Selma Tosun1, Hülya Ozkan Ozdemir1, Esin Erdogan2, Seniz Akcay3, Murat Aysin4, Neslihan Eskut5, Pınar Ortan5, Burak Eskut6. 1. Izmir Bozyaka Education and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Izmir, Turkey. 2. Department of Psychiatry, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey. 3. Department of Physical Medicine and Rehabilitation, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey. 4. Faculty of Medicine, Department of Public Health, Izmir Katip Celebi University, Izmir, Turkey. 5. Department of Neurology, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey. 6. Department of Chest Diseases, University of Izmir Katip Celebi, Ataturk Education and Research Hospital, Izmir, Turkey.
Abstract
OBJECTIVES: Numerous vaccination studies are conducted to protect against COVID-19 infection, and preclinical and clinical studies are still ongoing worldwide. During this extraordinary period, the necessity to perform COVID-19 vaccine studies and immunization programs together has emerged. Vaccine Adverse Effects (VAEs) need to be documented quickly. We aimed to determine the VAEs and to compare the frequency of VAEs between groups according to sociodemographic characteristics after the inactivated vaccine (CoronaVac) was administered to healthcare workers (HCWs) in Turkey. METHODS: An online questionnaire was delivered to 4040 volunteer HCWs across the whole country who were vaccinated with CoronaVac. Sociodemographic characteristics, medical history, history of COVID-19 infection, and VAEs occurring after the first and second doses of the inactivated vaccine were evaluated. RESULTS: The most common local and systemic VAEs after first and second doses of the COVID-19 vaccine were reported as, pain at the injection site (37.9%; 37.6%), headache (21.5%; 16.8%), fatigue (18%; 15%), drowsiness (9.6%; 8.2%), back pain (8.8%; 8.2%), nausea (6.3%; 4.8%), and joint pain (4.7%; 4.7%). Individuals with a history of allergies (generalized or vaccine-related) and females had a higher rate of VAE. Participants aged 60 and over reported less frequent VAEs. CONCLUSION: It is extremely important to identify and document the VAEs occurring in the early postvaccination period in different groups of the community. These initial findings may provide reassurance to healthcare providers and vaccine recipients and promote confidence in the safety of this inactive COVID-19 vaccine, however longitudinal follow-up studies are recommended.
OBJECTIVES: Numerous vaccination studies are conducted to protect against COVID-19 infection, and preclinical and clinical studies are still ongoing worldwide. During this extraordinary period, the necessity to perform COVID-19 vaccine studies and immunization programs together has emerged. Vaccine Adverse Effects (VAEs) need to be documented quickly. We aimed to determine the VAEs and to compare the frequency of VAEs between groups according to sociodemographic characteristics after the inactivated vaccine (CoronaVac) was administered to healthcare workers (HCWs) in Turkey. METHODS: An online questionnaire was delivered to 4040 volunteer HCWs across the whole country who were vaccinated with CoronaVac. Sociodemographic characteristics, medical history, history of COVID-19 infection, and VAEs occurring after the first and second doses of the inactivated vaccine were evaluated. RESULTS: The most common local and systemic VAEs after first and second doses of the COVID-19 vaccine were reported as, pain at the injection site (37.9%; 37.6%), headache (21.5%; 16.8%), fatigue (18%; 15%), drowsiness (9.6%; 8.2%), back pain (8.8%; 8.2%), nausea (6.3%; 4.8%), and joint pain (4.7%; 4.7%). Individuals with a history of allergies (generalized or vaccine-related) and females had a higher rate of VAE. Participants aged 60 and over reported less frequent VAEs. CONCLUSION: It is extremely important to identify and document the VAEs occurring in the early postvaccination period in different groups of the community. These initial findings may provide reassurance to healthcare providers and vaccine recipients and promote confidence in the safety of this inactive COVID-19 vaccine, however longitudinal follow-up studies are recommended.
Authors: Hanan M Fathi; Iman I El Gazzar; Mervat I Abd Elazeem; Enas AboulKheir; Nada M Gamal; Faten Ismail; Rawhya R El Shereef; Samar Tharwat; Shereen Elwan; Nermeen Samy; Noha Abdel Baki; Nora Y Elsaid; Amany S El-Bahnasawy; Abdelhfeez Moshrif; Yousra Abdel Fattah; Marwa A Amer; Maha E Ibrahim; Noha M Khalil; Soha El-Dessouki; Nouran Abaza; Amira T El-Shanawany; Eman F Mohamed; Nehal El-Ghobashy; Neveen Ayoub; Othman Hammam; Samar Fawzy; Safaa Sayed; Tamer A Gheita; Nevin Hammam Journal: Rheumatol Int Date: 2022-04-16 Impact factor: 3.580